AlzeCure Pharma AB (publ) announced that the company's presentation at the Alzheimer's conference AD/PD 2023 is now available in its entirety on the company's website. The presentation contains new preclinical data with the company's leading clinical drug candidate NeuroRestore ACD856, which is being developed with a focus on Alzheimer's disease. The abstract, titled Effects on neuroprotection and neuroplasticity by the clinical compound ACD856, a novel positive modulator of Trk-receptors from the NeuroRestore® platform, was presented by Johan Sandin, CSO, contains new preclinical results with ACD856, the leading drug candidate in the NeuroRestore platform.

The results from the preclinical studies showed that ACD856 has a neuroprotective effect and increases the amount of SNAP25, a protein that is linked to the contact surfaces between nerve cells, so-called synapses, which disappear and lead to the classical symptoms of Alzheimer's disease. Furthermore, positive, persistent long-term effects were also observed, suggesting effects on neuronal plasticity, a phenomenon that plays an important role in cognitive function. ACD856, which is a positive modulator of both NGF/TrkA- and BDNF/TrkB-mediated signaling, has been shown in previous preclinical studies to improve learning and memory and is being developed primarily for the treatment of Alzheimer's disease.

The drug candidate recently completed phase I clinical trials where both good safety and tolerability were observed in humans, and that ACD856 crossed the blood-brain barrier and activated regions of the brain central to both cognition and depression treatment. The other co-authors of the abstract are Sanja Juric, Cristina Parrado-Fernández, Nather Madjid, Gunnar Nordvall, Maria Backlund, Märta Dahlström and Pontus Forsell.